EnCoRe MoMS:Engaging Communities to Reduce Morbidity From Maternal Sepsis : EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis
Maternal sepsis is the second leading cause of maternal death, major cause of morbidity, and preventable in most cases. EnCoRe MoMS: Engaging Communities to Reduce Morbidity from Maternal Sepsis will (Aim 2) Develop algorithms to optimize prediction of sepsis around delivery and postpartum.In the UG3 phase, robust community engagement and research infrastructures were established to: Aim 2a. Create a rich electronic health records (EHR) database from the Perinatal Research Consortium (PRC). Aim 2b. Collate neighborhood-level datasets characterizing social determinants of health (SDOH)In the UH3 phase, the investigators will Aim 2c. Harmonize patient-level EHR and neighborhood-level SDOH datasets and use machine learning models to analyze the individual and joint contributions of patient and neighborhood factors to optimize sepsis risk prediction within the PRC sample..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ClinicalTrials.gov - (2023) vom: 28. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: November 28, 2023, Last downloaded: ClinicalTrials.gov processed this data on December 06, 2023, Last updated: December 06, 2023 |
|---|
| Study ID: |
NCT06148532 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG009510494 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG009510494 | ||
| 003 | DE-627 | ||
| 005 | 20231206010519.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231129s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG009510494 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT06148532 | ||
| 035 | |a (UBBS_Klinische_Studien)AAAU3697 - Aim 2 | ||
| 035 | |a (UBBS_Klinische_Studien)1UG3HD111247 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a EnCoRe MoMS:Engaging Communities to Reduce Morbidity From Maternal Sepsis |b EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: November 28, 2023, Last downloaded: ClinicalTrials.gov processed this data on December 06, 2023, Last updated: December 06, 2023 | ||
| 520 | |a Maternal sepsis is the second leading cause of maternal death, major cause of morbidity, and preventable in most cases. EnCoRe MoMS: Engaging Communities to Reduce Morbidity from Maternal Sepsis will (Aim 2) Develop algorithms to optimize prediction of sepsis around delivery and postpartum.In the UG3 phase, robust community engagement and research infrastructures were established to: Aim 2a. Create a rich electronic health records (EHR) database from the Perinatal Research Consortium (PRC). Aim 2b. Collate neighborhood-level datasets characterizing social determinants of health (SDOH)In the UH3 phase, the investigators will Aim 2c. Harmonize patient-level EHR and neighborhood-level SDOH datasets and use machine learning models to analyze the individual and joint contributions of patient and neighborhood factors to optimize sepsis risk prediction within the PRC sample. | ||
| 650 | 2 | |a Sepsis | |
| 650 | 2 | |a Toxemia | |
| 650 | 2 | |a Pregnancy Complications, Infectious | |
| 650 | 4 | |a Study Type: Observational | |
| 650 | 4 | |a Recruitment Status: Enrolling by invitation | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2023) vom: 28. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:28 |g month:11 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT06148532 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 28 |c 11 | ||